Dopamine control of aldosterone secretion in end-stage renal failure.
The role of the tonic inhibitory effect of dopamine on aldosterone secretion has been investigated in 10 patients with chronic renal failure (CRF) on hemodialysis, in 8 normotensive renal transplant recipients (Tx) with normal renal function and in 8 normotensive volunteers (NV). The following tests were performed: the response of plasma aldosterone (PA) to metoclopramide administration; the response of plasma prolactin (PRL) to TRH administration, and the changes induced by Lisuride (a dopaminergic agonist, on the values of PA and PRL). The basal values of PA and PRL were higher in CRF than in NV and Tx. The inverse was true for plasma renin activity (PRA) values. The response of PA and PRL to metoclopramide showed blunted increases in CRF when compared to NV, in the absence of changes of PRA, cortisol and potassium. After TRH administration, PRL increase in CRF was also inferior. Lisuride induced a decrease of both PA and PRL both in CRF and NV. In Tx, basal values of PA and PRL were similar to NV. Nevertheless, the response to metoclopramide and TRH were partially blunted when compared to that of NV. These results point to the existence of a deranged dopaminergic regulation of aldosterone secretion in end-stage renal failure patients. The alterations are partially corrected by a well-functioning kidney graft.
D000328:Adult; D000450:Aldosterone / Q000097:blood*; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008090:Lisuride / Q000494:pharmacology; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011388:Prolactin / Q000097:blood*; D012083:Renin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D000450:Aldosterone; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D008090:Lisuride; D012083:Renin; D008787:Metoclopramide; D011188:Potassium; D004298:Dopamine